For the quarter ending 2025-09-30, CERO had -$1,280,602 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net Income Loss | -4,856,395 | -10,523,246 |
| Net loss-Successor | -4,856,395 | -10,523,246 |
| Depreciation expense-Successor | 69,354 | 145,715 |
| Stock-based compensation-Successor | 348,116 | 488,274 |
| Amortization of right-to-use operating lease asset-Successor | 203,412 | 391,417 |
| Write off of deferred offering costs-Successor | 500,000 | - |
| Stock-based inducement expense-Successor | 0 | 863,550 |
| Foreign currency transaction gain included in other income (expenses)-Successor | 248 | - |
| Prepaid expenses and other current assets-Successor | 87,935 | 169,143 |
| Accounts payable-Successor | 864,545 | 561,901 |
| Accrued liabilities-Successor | -24,369 | -404,289 |
| Operating lease liability-Successor | -221,595 | -422,881 |
| Depreciation expense | 215,069 | - |
| Write off of deferred offering costs | 500,000 | - |
| Gain from settlement of liabilities with vendors | 0 | - |
| Gain from settlement of liabilities with vendors-Successor | 0 | - |
| Amortization of debt discount-Successor | 0 | - |
| Gain on revaluation of earnout and derivative liabilities-Successor | 0 | - |
| Net cash used in operating activities | -3,205,115 | -9,068,702 |
| Proceeds from sale of equity securities | 500,000 | - |
| Proceeds received from sale of series b preferred stock | - | 0 |
| Net cash provided by investing activities | 500,000 | - |
| Proceeds from exercise of series a preferred warrants | 0 | 500,000 |
| Proceeds from share purchases and collection of stock subscription receivables under eloc, net of issuance costs | 1,278,217 | 2,425,906 |
| Proceeds received from sale of series d preferred stock | 2,560,981 | - |
| Proceeds received from sale of common stock and warrants | 0 | 588,000 |
| Proceeds received from sale of pre-funded warrants, net of issuance costs | 0 | 3,685,027 |
| Payment of deferred offering costs | 174,505 | - |
| Proceeds from exercise of pre-funded warrants | 0 | 203 |
| Cash redemption of series c preferred stock | 0 | 395,000 |
| Proceeds from issuance of series a preferred stock, net of issuance costs | 0 | 0 |
| Advances from shareholder | 0 | 0 |
| Payment of sponsor loans | 0 | 0 |
| Proceeds from short term borrowings, net | 0 | 0 |
| Payments for short term borrowings | 0 | 0 |
| Proceeds received from sale of series b preferred stock | 0 | - |
| Proceeds received from sale of series c preferred stock, net of issuance costs of 434,428 | -2,240,180 | 2,240,180 |
| Net cash provided by financing activities | 1,424,513 | 9,044,316 |
| Net increase (decrease) in cash, restricted cash and cash equivalents | -1,280,602 | -24,386 |
| Cash and cash equivalents at beginning of period | 3,327,060 | - |
| Cash and cash equivalents at end of period | 2,022,072 | - |
CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC. (CERO)